提炼
肺动脉高压(PH)是一种高度病态说ease defined foremost by elevated mean pulmonary artery pressure (mPAP) measured during right heart catheterisation (RHC) at rest. Patients are classified further into one of three PH haemodynamic subgroups based on specific pulmonary artery wedge pressure (PAWP) and pulmonary vascular resistance (PVR) thresholds: pre-capillary PH (PAWP ≤15 mmHg+PVR ≥3.0 Wood units (WU)), isolated post-capillary PH (PAWP >15 mmHg+PVR <3.0 WU) and combined pre-/post-capillary PH (PAWP >15 mmHg+PVR ≥3.0 WU) [1].
Abstract
这些数据说明了基于多个右心导管插入测量的风险连续性,同时识别肺动脉楔压> 15 mmHg,<12 mmHg尤其是高风险https://bit.ly/3whdeov
Footnotes
Data availability: The data from the study cohort that support the findings of this study are available from the corresponding author on reasonable request, although they will be subject to the stringent data privacy rules of the Veterans Affairs Healthcare System and the US Government.
利益冲突:W.M.奥尔德姆没有什么可披露的。
利益冲突:E。Hess无话可说。
利益冲突:S.W。沃尔多(Waldo)从Abiomed,心血管系统成立和Janssen Pharmaceuticals(丹佛研究所的研究赠款)报告(在提交工作之外)。
利益冲突:洪伯特先生报告了在提交工作之外的Actelion,Acceleron,Bayer和Merck的个人费用。
利益冲突:G。Choudhary无需透露。
利益冲突:学士学位Maron在提交的工作之外报告了Actelion的个人费用;并拥有美国专利9,605,047,美国专利PCT/US2019/059890待定,以及临时专利申请62475955和029672待定。
Support statement: B.A. Maron: R01HL139613-01, R01HL1535-02, R01HL155096-01, U54HL119145, R21HL145420; Cardiovascular Medical Research Education Foundation (CMREF), and McKenzie Family Charitable Trust, Boston Biomedical Innovations Center. W.M. Oldham: K08HL128802, CMREF; G. Choudhary: VA CSR&D grant I01CX001892, and NHLBI R01HL148727. Funding information for this article has been deposited with theCrossRef资助人注册表。所表达的观点是作者的观点,并不代表退伍军人事务或其他美国联邦政府机构的观点。
- Received2020年12月23日。
- 公认马克h 27, 2021.
- 这项工作的内容不受版权的影响。设计和品牌是版权©ERS2021。用于商业复制权和权限联系权限{at} ersnet.org